First analysis of the Myasthenia Gravis SPOTLIGHT Registry: outcomes with eculizumab and ravulizumab.
James F Howard, Dubravka Dodig, Lida Zeinali...
https://pubmed.ncbi.nlm.nih.gov/40812271/Actively Recruiting
Led by Alexion Pharmaceuticals, Inc. · Updated on 2026-02-18
500
Participants Needed
51
Research Sites
N/A
Total Duration
This research aims to collect long-term data on patients with generalized myasthenia gravis gMG who are prescribed Alexion complement C5 inhibition therapies, including eculizumab Soliris and ravulizumab Ultomiris. It is an observational, multinational registry designed to monitor clinical outcomes and safety over time in a real-world setting. The study is led by Alexion Pharmaceuticals, Inc. and involves multiple centers worldwide. Participants who join the registry will have their medical history and gMG treatment history reviewed retrospectively at enrollment. After joining, data will be gathered prospectively during routine clinical care visits and through patient-reported outcomes, all collected electronically. The registry maintains observation and data collection for up to five years from the day of enrollment. During the study, participants will be asked to attend routine visits where their clinical status, including the Myasthenia Gravis Activities of Daily Living MG-ADL score, will be assessed. Researchers will track changes in these scores approximately five years after enrollment to understand long-term outcomes. The study does not involve any experimental treatments but monitors patients receiving prescribed Alexion therapies as part of their usual care.
CONDITIONS
Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
A
Alexion Pharmaceuticals, Inc. (Sponsor)
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Alexion Pharmaceuticals, Inc.
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 5 years from enrollment
Participants who undergo routine care are observed with data collected from their medical history and ongoing clinical care for generalized myasthenia gravis.
Periodic data collection through routine clinical care and patient-reported outcomes
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Have more questions? Get in touch with our team for quick support
James F Howard, Dubravka Dodig, Lida Zeinali...
https://pubmed.ncbi.nlm.nih.gov/40812271/Alexion Pharmaceuticals, Inc.
Lead Sponsor